![[Preprint] RCT: In patients with COVID-19 and severe hypoxia, dexamethasone 12 mg did NOT result in statistically significant improved outcomes compared to dexamethasone 6 mg – “Mortality at 28 days was 27.1% and 32.3% in patients assigned to 12 mg and 6](/media/k2/items/cache/306600c868fe6b67afe34e9f7a9f98b7_L.jpg)
[Preprint] RCT: In patients with COVID-19 and severe hypoxia, dexamethasone 12 mg did NOT result in statistically significant improved outcomes compared to dexamethasone 6 mg – “Mortality at 28 days was 27.1% and 32.3% in patients assigned to 12 mg and 6
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxia: an international, randomized, blinded trial – medRxiv
The post [Preprint] RCT: In patients with COVID-19 and severe hypoxia, dexamethasone 12 mg did NOT result in statistically significant improved outcomes compared to dexamethasone 6 mg – “Mortality at 28 days was 27.1% and 32.3% in patients assigned to 12 mg and 6 mg, respectively (adjusted relative risk 0.86, 99% CI, 0.68-1.08)”. appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- M-A | Catheter-directed thrombolysis vs. systemic thrombolysis and anticoagulation in intermediate- or high-risk pulmonary embolism
- AHA Scientific Statement | Pulmonary hypertension in congenital heart disease
- RCT | Cytisinicline shows significant efficacy in smoking cessation over placebo
- M-A | Adjunctive corticosteroids improve survival, clinical outcomes in severe community-acquired pneumonia
- M-A | Drug therapies for treatment of idiopathic pulmonary fibrosis